Inhibrx Biosciences Profit Margin

Inhibrx Biosciences (INBX) currently reports a profit margin of -10014.23% as of March 2026. That compares with 861485.5% in the prior-year period — down 101.2% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Inhibrx Biosciences's profit margin history and peer comparisons.

Inhibrx Biosciences's profit margin decreased from 861485.5% to -10014.23% — a 101.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Inhibrx Biosciences's profit margin of -10014.23% is lower than the Healthcare sector average of 15.29%. That is roughly 65582.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Inhibrx Biosciences's current -10014.23% should be judged against Healthcare norms (sector average: 15.29%) and against INBX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -10014.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Inhibrx Biosciences, and consider following INBX for alerts when major investors trade the stock.